Videos

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

A study of the use of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab suggested a role for the strategy in this patient population.

“As the number of AYA survivors continues to grow, there is a pressing need for targeted information, education, and intervention around sexual health, intimate relationships, and body image,” the Children’s Oncology Group (COG) AYA Oncology Discipline Committee wrote in a review.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about what she intends to evaluate for a patient population with multiple myeloma and diabetes moving forward.

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

An expert in multiple myeloma spoke about the most exciting research to come out of 2020 and what research he hopes to see in 2021.

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.

Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about the implications of a study which evaluated the impact of diabetes in patients with multiple myeloma.

An expert in urologic oncology seeks to answer further questions regarding the use of telemedicine for this patient population.

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

Guido Lancman, MD, sought to evaluate the effect of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab.

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.

Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high-risk prostate cancers.

Clinician Lisa La sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in patients with diabetes versus those without who were enrolled in the CONNECT MM Registry.

Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.

The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).

The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.